This ‘Insomnia - Epidemiology Forecast-2032' report delivers an in-depth understanding of Insomnia, historical and forecasted epidemiology as well as the Insomnia trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
According to the International Classification of Sleep Disorders 3rd edition criteria, Insomnia disorder is defined as complaints of difficulty initiating sleep (DIS), and/or difficulty maintaining sleep (DMS), and/or early morning awakenings (EMA). These nocturnal symptoms must be accompanied by daytime impairment related to sleeping difficulties.
Whereas DSM-V defines Insomnia as dissatisfaction with sleep quantity or quality, often associated with either difficulty initiating sleep or difficulty maintaining sleep. It is characterized by frequent awakenings or problems returning to sleep after awakenings. This sleep difficulty is present for at least 3 months or occurs at least 3 nights per week. The condition has been renamed Insomnia disorder.
There is no single established cause of insomnia. However, research suggests that in many people, it results from certain physiological arousal at unwanted times, disrupting standard sleep patterns. Such arousal can include a heightened heart rate, a higher body temperature, and increased levels of specific hormones like cortisol. It also often occurs along with various mental disorders.
Insomnia was previously subdivided into many different types, including primary and secondary insomnia. Recently, these categories were changed American Academy of Sleep Medicine categorizes insomnia into short-term insomnia, chronic insomnia, and other insomnia. Other previously used subtypes now under chronic insomnia included paradoxical insomnia, idiopathic insomnia, psychophysiological insomnia, and inadequate sleep hygiene, among others. These subtypes were recently removed in the new ICSD-III.
Chronic Insomnia is when a person experiences sleeping difficulties and related daytime symptoms, like fatigue and attention issues, at least 3 days per week for more than 3 months or repeatedly over the years. Short-term insomnia r involves the same sleep difficulties and symptoms as chronic, but those problems are experienced for less than 3 months and may not occur three times per week. In specific cases, a doctor may diagnose a condition called other insomnia disorder if a person has significant sleeping problems but does not meet all of the criteria for either chronic or short-term insomnia disorder.
Increasing age, female gender, medical and psychiatric disease, and shift work all independently predict the risk of developing chronic insomnia. Insomnia is more prevalent in older populations, and the elderly are prone to several concomitant risk factors, such as increased prescription drug use, somatic disorders, neurological decline, reduced exposure to outdoor light, and polyphasic sleep-wake patterns. Lack of physical activity also may play a role in the age-related increase in insomnia prevalence.
Questionnaires such as the Insomnia Severity Index (ISI) and the Pittsburgh Sleep Quality Index (PSQI) is a tools to aid in the diagnosis of insomnia. The Insomnia Severity Index consists of seven questions with a score of 1-4. The maximum score is 28, and the higher the score, the worse insomnia. A score of greater than 14 indicates clinical insomnia. The questionnaire can be self-administered by patients and brought in for evaluation by the provider. The PSQI was developed to help differentiate between different sleep-related disorders. It consists of 19 questions and measures different domains of sleep (quality, latency, duration, efficacy, medication use, daytime symptoms, and disturbances) over a month.
Insomnia Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Insomnia, Type-specific Cases of Insomnia, Gender-specific Cases of Insomnia, and Age-specific Cases of Insomnia scenario of Insomnia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.
Insomnia Detailed Epidemiology Segmentation
Insomnia Disease Understanding
Insomnia is a common sleep-wake disorder characterized by both nocturnal and diurnal symptoms. It involves a predominant complaint of dissatisfaction with sleep quality or duration. It is accompanied by difficulties initiating sleep at bedtime, frequent or prolonged awakenings, or early-morning awakening with an inability to return to sleep. According to the American Academy of Sleep Medicine, Insomnia is defined as difficulty falling or staying asleep accompanied by daytime impairments related to those sleep troubles.According to the International Classification of Sleep Disorders 3rd edition criteria, Insomnia disorder is defined as complaints of difficulty initiating sleep (DIS), and/or difficulty maintaining sleep (DMS), and/or early morning awakenings (EMA). These nocturnal symptoms must be accompanied by daytime impairment related to sleeping difficulties.
Whereas DSM-V defines Insomnia as dissatisfaction with sleep quantity or quality, often associated with either difficulty initiating sleep or difficulty maintaining sleep. It is characterized by frequent awakenings or problems returning to sleep after awakenings. This sleep difficulty is present for at least 3 months or occurs at least 3 nights per week. The condition has been renamed Insomnia disorder.
There is no single established cause of insomnia. However, research suggests that in many people, it results from certain physiological arousal at unwanted times, disrupting standard sleep patterns. Such arousal can include a heightened heart rate, a higher body temperature, and increased levels of specific hormones like cortisol. It also often occurs along with various mental disorders.
Insomnia was previously subdivided into many different types, including primary and secondary insomnia. Recently, these categories were changed American Academy of Sleep Medicine categorizes insomnia into short-term insomnia, chronic insomnia, and other insomnia. Other previously used subtypes now under chronic insomnia included paradoxical insomnia, idiopathic insomnia, psychophysiological insomnia, and inadequate sleep hygiene, among others. These subtypes were recently removed in the new ICSD-III.
Chronic Insomnia is when a person experiences sleeping difficulties and related daytime symptoms, like fatigue and attention issues, at least 3 days per week for more than 3 months or repeatedly over the years. Short-term insomnia r involves the same sleep difficulties and symptoms as chronic, but those problems are experienced for less than 3 months and may not occur three times per week. In specific cases, a doctor may diagnose a condition called other insomnia disorder if a person has significant sleeping problems but does not meet all of the criteria for either chronic or short-term insomnia disorder.
Increasing age, female gender, medical and psychiatric disease, and shift work all independently predict the risk of developing chronic insomnia. Insomnia is more prevalent in older populations, and the elderly are prone to several concomitant risk factors, such as increased prescription drug use, somatic disorders, neurological decline, reduced exposure to outdoor light, and polyphasic sleep-wake patterns. Lack of physical activity also may play a role in the age-related increase in insomnia prevalence.
Insomnia Diagnosis
Diagnosis of insomnia is based on the subjective complaint of difficulties initiating or maintaining sleep and reports of substantial distress or daytime impairments. Currently, two modalities help with objectively measuring sleep activity: actigraphy and polysomnography. Actigraphy is a technique for measuring limb movement activity with actigraphic devices that are wearable on wrists or ankles. The data for movement activity is gathered over a period, ultimately giving patterns for wakefulness and sleep. With the patterns, general sleep parameters, including sleep latency, sleep efficiency, total sleep time, and wake after sleep onset, can be obtained. These parameters greatly aid in evaluating insomnia. Non-REM and REM sleep cycles, however, can not be gathered and need polysomnography to assess. Although polysomnography is the golden standard in measuring sleep-related disorders, it is not used routinely for diagnosing insomnia. In insomnia cases, it is usually indicated when there is suspicion that another sleep-related disorder is possible. Such conditions would include breathing disorders such as obstructive sleep apnea, central sleep apnea, or sleep-related movement disorders.Questionnaires such as the Insomnia Severity Index (ISI) and the Pittsburgh Sleep Quality Index (PSQI) is a tools to aid in the diagnosis of insomnia. The Insomnia Severity Index consists of seven questions with a score of 1-4. The maximum score is 28, and the higher the score, the worse insomnia. A score of greater than 14 indicates clinical insomnia. The questionnaire can be self-administered by patients and brought in for evaluation by the provider. The PSQI was developed to help differentiate between different sleep-related disorders. It consists of 19 questions and measures different domains of sleep (quality, latency, duration, efficacy, medication use, daytime symptoms, and disturbances) over a month.
Insomnia Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Insomnia, Type-specific Cases of Insomnia, Gender-specific Cases of Insomnia, and Age-specific Cases of Insomnia scenario of Insomnia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.
Insomnia Detailed Epidemiology Segmentation
- In 2021, the total diagnosed prevalent cases of insomnia were estimated to be approximately 85,968,021 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.6% during the study period (2019-2032).
- Among the 7MM, the United States accounted for nearly 67% of the total diagnosed prevalent cases of insomnia in the year 2021. These cases are expected to increase further during the study period (2019-2032).
- As per analysis, in the US, there were approximately 31,564,128 cases of acute insomnia and 26,086,057 cases of chronic insomnia in 2021, which are expected to increase by 2032.
- According to estimates based on the publisher's epidemiology model of Insomnia, the age-specific cases of insomnia in EU4 and the UK in 2021 were approximately 2,206,746, 3,715,978, 3,751,031, 3,969,639, 4,000,375, and 5,498,193 cases in the age groups 18-24, 25-34, 35-44, 45-54, 55-64, and 65+, respectively.
- In 2021, in Japan, there were approximately 2,252,023 cases of insomnia in males, and 2,923,851 cases of insomnia in females. These gender-specific cases are expected to decrease by 2032 in Japan.
- According to estimates based on the publisher's epidemiology model of insomnia, in 2021, in EU4 and the UK, there were approximately 9,836,407 cases of acute insomnia and 13,305,555 cases of chronic insomnia, which are expected to increase by 2032.
Scope of the Report
- The report covers a descriptive overview of Insomnia, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
- The report assesses the disease risk and burden of Insomnia.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for the 7MM, Total Diagnosed Prevalent Cases of Insomnia, Type-specific CDases of Insomnia, Gender-specific Cases of Insomnia, and Age-specific Cases of Insomnia.
Report Highlights
- 11-Year Forecast of Insomnia
- The 7MM Coverage
- Total Diagnosed Prevalent Cases of Insomnia
- Type-specific Cases of Insomnia
- Gender-specific Cases of Insomnia
- Age-specific Cases of Insomnia
Key Questions Answered
- What are the disease risk and burdens of Insomnia?
- What is the historical Insomnia patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
- What would be the forecasted patient pool of Insomnia at the 7MM level?
- What will be the growth opportunities across the 7MM concerning the patient population with Insomnia?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Insomnia during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Reasons to Buy
The Insomnia report will allow the user to -- Develop business strategies by understanding the trends shaping and driving the 7MM Insomnia epidemiology forecast.
- The Insomnia epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
- The Insomnia epidemiology model developed by the publisher is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Table of Contents
1. Key Insights2. Report Introduction
3. Insomnia Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Insomnia in 2019
3.2. Patient Share (%) Distribution of Insomnia in 2032
4. Methodology of Insomnia Epidemiology
5. Executive Summary of Insomnia
6. Disease Background and Overview
6.1. Introduction
6.2. Classification of Insomnia
6.3. Causes
6.4. Sign and Symptoms
6.5. Risk Factors
6.6. Pathophysiology
6.6.1. Molecular Mechanisms of Sleep and Insomnia
6.6.2. Cellular Mechanisms of Sleep and Insomnia
6.6.3. Sleep-wake Regulation and Neural Circuitry of Sleep
6.6.4. Electrophysiologic and Physiologic Dysregulation in Insomnia
6.6.5. Behavioral and Cognitive Contributions to Insomnia
6.7. Diagnosis
6.7.1. Diagnosis guidelines
6.7.1.1. European Sleep Research Society Guidelines for the Treatment of Insomnia
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale: The 7MM
7.2.1. Diagnosed prevalent cases of Insomnia
7.2.2. Type-specific cases of Insomnia
7.2.3. Gender-specific cases of Insomnia
7.2.4. Age-specific cases of Insomnia
7.2.5. Treated cases of Insomnia
7.3. Total diagnosed prevalent cases of Insomnia in the7MM
7.4. The US
7.4.1. Total diagnosed prevalent cases of Insomnia in the US
7.4.2. Type-specific cases of Insomnia in the US
7.4.3. Gender-specific cases of Insomnia in the US
7.4.4. Age-specific cases of Insomnia in the US
7.5. EU4 and the UK
7.5.1. Total diagnosed prevalent cases of Insomnia in EU4 and the UK
7.5.2. Type-specific cases of Insomnia in EU4 and the UK
7.5.3. Gender-specific cases of Insomnia in EU4 and the UK
7.5.4. Age-specific cases of Insomnia in EU4 and the UK
7.5.5. Germany
7.5.5.1. Total diagnosed prevalent cases of Insomnia in Germany
7.5.5.2. Type-specific cases of Insomnia in Germany
7.5.5.3. Gender-specific cases of Insomnia in Germany
7.5.5.4. Age-specific cases of Insomnia in Germany
7.5.6. France
7.5.6.1. Total diagnosed prevalent cases of Insomnia in France
7.5.6.2. Type-specific cases of Insomnia in France
7.5.6.3. Gender-specific cases of Insomnia in France
7.5.6.4. Age-specific cases of Insomnia in France
7.5.7. Italy
7.5.7.1. Total diagnosed prevalent cases of Insomnia in Italy
7.5.7.2. Type-specific cases of Insomnia in Italy
7.5.7.3. Gender-specific cases of Insomnia in Italy
7.5.7.4. Age-specific cases of Insomnia in Italy
7.5.8. Spain
7.5.8.1. Total diagnosed prevalent cases of Insomnia in Spain
7.5.8.2. Type-specific cases of Insomnia in Spain
7.5.8.3. Gender-specific cases of Insomnia in Spain
7.5.8.4. Age-specific cases of Insomnia in Spain
7.5.9. The UK
7.5.9.1. Total diagnosed prevalent cases of Insomnia in the UK
7.5.9.2. Type-specific cases of Insomnia in the UK
7.5.9.3. Gender-specific cases of Insomnia in the UK
7.5.9.4. Age-specific cases of Insomnia in the UK
7.6. Japan
7.6.1. Total diagnosed prevalent cases of Insomnia in Japan
7.6.2. Type-specific cases of Insomnia in Japan
7.6.3. Gender-specific cases of Insomnia in Japan
7.6.4. Age-specific cases of Insomnia in Japan
8. Patient Journey
9. Key Opinion Leaders' Views
10. Unmet Need
11. Appendix
11.1. Bibliography
11.2. Acronyms and Abbreviations
11.3. Report Methodology
12. Publisher Capabilities
13. Disclaimer
14. About the Publisher
List of Tables
Table 1: Summary of Insomnia Epidemiology (2019-2032)
Table 2: Classification of Insomnia
Table 3: Causes of Insomnia
Table 4: European Guidelines for the Diagnosis of Insomnia
Table 5: Total Diagnosed Prevalent Cases of Insomnia in the 7MM, in thousands (2019-2032)
Table 6: Total Diagnosed Prevalent Cases of Insomnia in the US, in thousands (2019-2032)
Table 7: Type-specific Cases of Insomnia in the US, in thousands (2019-2032)
Table 8: Gender-specific Cases of Insomnia in the US, in thousands (2019-2032)
Table 9: Age-specific Cases of Insomnia in the US, in thousands (2019-2032)
Table 10: Total Diagnosed Prevalent Cases of Insomnia in EU4 and the UK, in thousands (2019-2032)
Table 11: Type-specific Cases of Insomnia in EU4 and the UK, in thousands (2019-2032)
Table 12: Gender-specific Cases of Insomnia in EU4 and the UK, in thousands (2019-2032)
Table 13: Age-specific Cases of Insomnia in EU4 and the UK, in thousands (2019-2032)
Table 14: Total Diagnosed prevalent Cases of Insomnia in Germany, in thousands (2019-2032)
Table 15: Type-specific Cases of Insomnia in Germany, in thousands (2019-2032)
Table 16: Gender-specific Cases of Insomnia in Germany, in thousands (2019-2032)
Table 17: Age-specific Cases of Insomnia in Germany, in thousands (2019-2032)
Table 18: Total Diagnosed prevalent Cases of Insomnia in France, in thousands (2019-2032)
Table 19: Type-specific Cases of Insomnia in France, in thousands (2019-2032)
Table 20: Gender-specific Cases of Insomnia in France, in thousands (2019-2032)
Table 21: Age-specific Cases of Insomnia in France, in thousands (2019-2032)
Table 22: Total Diagnosed prevalent Cases of Insomnia in Italy, in thousands (2019-2032)
Table 23: Type-specific Cases of Insomnia in Italy, in thousands (2019-2032)
Table 24: Gender-specific Cases of Insomnia in Italy, in thousands (2019-2032)
Table 25: Age-specific Cases of Insomnia in Italy, in thousands (2019-2032)
Table 26: Total Diagnosed prevalent Cases of Insomnia in Spain, in thousands (2019-2032)
Table 27: Type-specific Cases of Insomnia in Spain, in thousands (2019-2032)
Table 28: Gender-specific Cases of Insomnia in Spain, in thousands (2019-2032)
Table 29: Age-specific Cases of Insomnia in Spain, in thousands (2019-2032)
Table 30: Total Diagnosed prevalent Cases of Insomnia in the UK, in thousands (2019-2032)
Table 31: Type-specific Cases of Insomnia in the UK, in thousands (2019-2032)
Table 32: Gender-specific Cases of Insomnia in the UK, in thousands (2019-2032)
Table 33: Age-specific Cases of Insomnia in the UK, in thousands (2019-2032)
Table 34: Total Diagnosed Prevalent Cases of Insomnia in Japan, in thousands (2019-2032)
Table 35: Type-specific Cases of Insomnia in Japan, in thousands (2019-2032)
Table 36: Gender-specific Cases of Insomnia in Japan, in thousands (2019-2032)
Table 37: Age-specific Cases of Insomnia in Japan, in thousands (2019-2032)
List of Figures
Figure 1: Symptoms of Insomnia
Figure 2: Risk Factors of Insomnia
Figure 3: Indicators of Hyperarousal in Insomnia
Figure 4: An Overview of the Flip-Flop Switch Model
Figure 5: CNS Pathways That are Potentially Involved in the Psychopathology of Insomnia
Figure 6: Diagnosis Algorithm of Insomnia
Figure 7: Total Diagnosed Prevalent Cases of Insomnia in the 7MM, in thousands (2019-2032)
Figure 8: Total Diagnosed Prevalent Cases of Insomnia in the US, in thousands (2019-2032)
Figure 9: Type-specific Cases of Insomnia in the US, in thousands (2019-2032)
Figure 10: Gender-specific Cases of Insomnia in the US, in thousands (2019-2032)
Figure 11: Age-specific Cases of Insomnia in the US, in thousands (2019-2032)
Figure 12: Total Diagnosed Prevalent Cases of Insomnia in EU4 and the UK, in thousands (2019-2032)
Figure 13: Type-specific Cases of Insomnia in EU4 and the UK, in thousands (2019-2032)
Figure 14: Gender-specific Cases of Insomnia in EU4 and the UK, in thousands (2019-2032)
Figure 15: Age-specific Cases of Insomnia in EU4 and the UK, in thousands (2019-2032)
Figure 16: Total Diagnosed prevalent Cases of Insomnia in Germany, in thousands (2019-2032)
Figure 17: Type-specific Cases of Insomnia in Germany, in thousands (2019-2032)
Figure 18: Gender-specific Cases of Insomnia in Germany, in thousands (2019-2032)
Figure 19: Age-specific Cases of Insomnia in Germany, in thousands (2019-2032)
Figure 20: Total Diagnosed prevalent Cases of Insomnia in France, in thousands (2019-2032)
Figure 21: Type-specific Cases of Insomnia in France, in thousands (2019-2032)
Figure 22: Gender-specific Cases of Insomnia in France, in thousands (2019-2032)
Figure 23: Age-specific Cases of Insomnia in France, in thousands (2019-2032)
Figure 24: Total Diagnosed prevalent Cases of Insomnia in Italy, in thousands (2019-2032)
Figure 25: Type-specific Cases of Insomnia in Italy, in thousands (2019-2032)
Figure 26: Gender-specific Cases of Insomnia in Italy, in thousands (2019-2032)
Figure 27: Age-specific Cases of Insomnia in Italy, in thousands (2019-2032)
Figure 28: Total Diagnosed prevalent Cases of Insomnia in Spain, in thousands (2019-2032)
Figure 29: Type-specific Cases of Insomnia in Spain, in thousands (2019-2032)
Figure 30: Gender-specific Cases of Insomnia in Spain, in thousands (2019-2032)
Figure 31: Age-specific Cases of Insomnia in Spain, in thousands (2019-2032)
Figure 32: Total Diagnosed prevalent Cases of Insomnia in the UK, in thousands (2019-2032)
Figure 33: Type-specific Cases of Insomnia in the UK, in thousands (2019-2032)
Figure 34: Gender-specific Cases of Insomnia in the UK, in thousands (2019-2032)
Figure 35: Age-specific Cases of Insomnia in the UK, in thousands (2019-2032)
Figure 36: Total Diagnosed Prevalent Cases of Insomnia in Japan, in thousands (2019-2032)
Figure 37: Type-specific Cases of Insomnia in Japan, in thousands (2019-2032)
Figure 38: Gender-specific Cases of Insomnia in Japan, in thousands (2019-2032)
Figure 39: Age-specific Cases of Insomnia in Japan, in thousands (2019-2032)
Figure 40: Patient Journey
Figure 41: Unmet Needs
